Want to understand how these updates are formatted? Check-out the FAQ.

Have any feedback? I’d love to hear you from - connect with me on LinkedIn. 📣

AstraZeneca Pharma India's Imfinzi (durvalumab) wins CDSCO approval for unresectable hepatocellular carcinoma treatment
Antibody, cancer, monoclonal antibody, hepatocellular carcinoma, PD-L1 inhibitor, immunotherapy - Read more

Taiwan Bio Therapeutics, Terumo partner to automate Treg manufacturing using Quantum Flex platform
Manufacturing agreement, cell therapy, autoimmune, R&D - Read more

Science 2 Sales builds and runs the entire outbound engine (across email, LinkedIn, and cold calling) for companies selling into biotech & pharma - so your sales team stops researching and starts closing qualified meetings with the decision-makers who can actually sign.

When it comes to outbound lead gen - you get the meetings. We handle everything else.

Learn more and book a free strategy call on our website.

Pfizer's atirmociclib hits Ph2 goal reducing death risk 40% in advanced breast cancer patients
Small molecule, cancer, CDK4/6 inhibitor, breast cancer, HR-positive HER2-negative - Read more

Priavoid's PRI-002 shows placebo-like ARIA rates targeting amyloid-beta oligomers in Alzheimer's disease Ph2 study
Peptide therapy, neurological, all-D-peptide, Alzheimer disease, amyloid-beta oligomers, ARIA avoidance - Read more

Ascendis Pharma's TransCon hGH (lonapegsomatropin) shows comparable efficacy to daily somatropin in Ph2 Turner syndrome trial
Protein therapy, rare disease, growth hormone, Turner syndrome, pediatric - Read more

R1 Therapeutics emerges with $77.5M series A funding for novel CKD phosphate control drug AP306
Small molecule, chronic kidney disease, major transaction, strategic - Read more

PerturbAI launches from stealth with largest in vivo CRISPR dataset spanning 8 million mouse brain cells
Gene therapy, cardiometabolic, strategic, operational - Read more

BioVie’s Option Therapeutics plans $20M IPO, developing liver disease drug treatment
Liver disease, small molecule, clinical-stage, rare disease - Read more

Mestag Therapeutics raises $40M, fibroblast-focused cancer strategy nearing Phase I trial
Cancer, bispecific antibody, fibroblast targeting, clinical-stage - Read more

iDEL Therapeutics raises $10M seed financing, advancing direct cytosolic transfer oncology pipeline
Oncology, platform technology, cytosolic delivery, solid tumors, preclinical - Read more

SAB BIO raises $85M public offering for autoimmune disease therapeutics development
Clinical-stage, autoimmune, antibody, type 1 diabetes - Read more

VST BIO raises $45M Series A, advancing stroke therapeutics platform
Stroke therapeutics, neurological, preclinical, platform technology - Read more

Indiana commits $1B to life sciences growth strategy targeting 100,000 new high-wage jobs over decade
Manufacturing, strategic, investment, major transaction - Read more

Xaira Therapeutics launches X-Cell virtual cell model trained on largest genome-wide perturbation dataset X-Atlas/Pisces
AI drug discovery platform, strategic, operational, investment - Read more

MHRA-NICE launch joint approval process to deliver new medicines to patients six months faster
Regulatory, strategic, operational, cost reduction - Read more

Innorna wins FDA clearance for Phase 1 study of mRNA therapy for refractory gout
mRNA therapy, metabolic disease, regulatory, strategic - Read more [Paywall]

Do you offer a biotech/pharma-focused product or service?

Or looking to get investor/analyst interest on your budding start-up?

Considering sponsoring TLDR Biotech to get in-front of an engaged audience of biotech & pharma-focused professionals.

Just reply to this email* or message me on LinkedIn to learn more.

*If you’re reading this on the web version, email [email protected]

FDA rejects Aldeyra Therapeutics' reproxalap for dry eye disease treatment for third time
Small molecule, ophthalmology, dry eye disease, reproxalap - Read more

Rhythm Pharmaceuticals' Imcivree fails Ph3 trial for melanocortin-4 receptor pathway-linked rare genetic obesity forms
Small molecule, metabolic, MC4R agonist, rare genetic obesity, weight loss - Read more

J&J closes New York JLABS incubator after 8 years, transitions operations to New York Genome Center
Incubator closure, operational, strategic, cost reduction - Read more

Bicycle Therapeutics cuts 30% workforce, shelves lead cancer drug zelenectide after regulatory roadblock
Antibody-drug conjugate, oncology, operational, cost reduction - Read more

Iran war disrupts Middle East drug shipments, threatening US generics supply and global pharmaceutical manufacturing costs
Generics, supply chain, operational, strategic - Read more

Have comments/questions/complaints about this newsletter?
Send me an email - I want your brutally honest feedback. 📝

If you find the content useful and think a colleague would too, please share TLDR Biotech with them! ♻️

And lastly - connect with me on LinkedIn!

Disclaimer: Content, news, research, tools, and mention of stock or tradeable securities are for educational and illustrative purposes only and do not imply a recommendation or solicitation to buy or sell a particular security or to engage in any particular investment strategy. Read the full terms & conditions here